Nkarta Inc. (NKTX): Price and Financial Metrics

Nkarta Inc. (NKTX): $12.67

-0.23 (-1.78%)

POWR Rating

Component Grades













Add NKTX to Watchlist
Sign Up

Industry: Biotech



in industry

NKTX Stock Price Chart Interactive Chart >

Price chart for NKTX

NKTX Price/Volume Stats

Current price $12.67 52-week high $40.64
Prev. close $12.90 52-week low $7.55
Day low $12.08 Volume 782,600
Day high $13.14 Avg. volume 1,959,380
50-day MA $12.52 Dividend yield N/A
200-day MA $17.34 Market Cap 418.24M

Nkarta Inc. (NKTX) Company Bio

Nkarta, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer. The company was founded by Dario Campana in 2005 and is headquartered in South San Francisco, CA.

NKTX Latest News Stream

Event/Time News Detail
Loading, please wait...

NKTX Latest Social Stream

Loading social stream, please wait...

View Full NKTX Social Stream

Latest NKTX News From Around the Web

Below are the latest news stories about Nkarta Inc that investors may wish to consider to help them evaluate NKTX as an investment opportunity.

William Blair Initiates a Buy Rating on Nkarta (NKTX)

William Blair analyst Sami Corwin initiated coverage with a Buy rating on Nkarta (NKTX – Research Report) today. The company's shares closed last Wednesday at $13.76, close to its 52-week low of $12.46. Currently, the analyst consensus on Nkarta is a Strong Buy with an average price target of $67.00. See Insiders’ Hot Stocks on TipRanks >> Based on Nkarta's latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $22.35 million. In comparison, last year the company had a GAAP net loss of $13.69 million.

Howard Kim on TipRanks | January 6, 2022

Do Institutions Own Nkarta, Inc. (NASDAQ:NKTX) Shares?

Every investor in Nkarta, Inc. ( NASDAQ:NKTX ) should be aware of the most powerful shareholder groups. Institutions...

Yahoo | January 5, 2022

Nkarta Receives U.S. FDA Orphan Drug Designation for NKX101 for Treatment of Patients with AML

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to NKX101 for treatment of acute myeloid leukemia (AML).

Intrado Digital Media | December 16, 2021

Nkarta Presents NKX019 Trial in Progress Poster at the 2021 ASH Annual Meeting and Exposition

SOUTH SAN FRANCISCO, Calif., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today presented a trial in progress poster on NKX019 for the treatment of relapsed and refractory B-cell malignancies at the 63 rd Annual Meeting and Exposition of the American Society of Hematology (ASH).

Intrado Digital Media | December 13, 2021

Charles Schwab Investment Management Inc. Has $3.41 Million Holdings in Nkarta, Inc. (NASDAQ:NKTX)

Charles Schwab Investment Management Inc. reduced its holdings in Nkarta, Inc. (NASDAQ:NKTX) by 9.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 107,615 shares of the companys stock after selling 11,482 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately []

Dakota Financial News | November 25, 2021

Read More 'NKTX' Stories Here

NKTX Price Returns

1-mo 63.06%
3-mo N/A
6-mo -27.64%
1-year -52.19%
3-year N/A
5-year N/A
YTD -17.46%
2021 -75.03%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.6491 seconds.